How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

When the Lung Master Protocol clinical trial (Lung-MAP or S1400) (1) was launched in June 2014, the goal of this first-of-its kind trial was simple: find effective treatments for seriously ill patients suffering from a specific type of lung cancer.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
Co-principal investigator, Lung-MAP trial;
Director, Thoracic Oncology Program, University of California, Davis
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center

YOU MAY BE INTERESTED IN

Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
Co-principal investigator, Lung-MAP trial;
Director, Thoracic Oncology Program, University of California, Davis
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center

Login